Roche/Genentech doubles down on tau, fronting $120M cash to ally on a 2-pronged strategy to fight Alzheimer’s
After butting up against repeated failures on the amyloid beta side of the R&D strategy for fighting Alzheimer’s, Roche is once again turning to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
